UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 919, 2015

LANTHEUS MEDICAL IMAGING, INC.

(Exact name of registrant as specified in its charter)

Delaware

333-169785

51-0396366

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

331 Treble Cove Road, North Billerica, MA 01862

(Address of principal executive offices) (Zip code)

Registrant’s telephone number, including area code: (978) 671-8001

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 78.01 ~~Regulation~~Other ~~FD Disclosure.~~Events

On June 919, 2015, ~~the registrant,~~ Lantheus Medical Imaging, Inc. (the “Company”) ~~commenced~~entered into ~~the marketing process for~~ a ~~proposed~~commercial ~~new~~supply ~~senior secured~~agreement ~~term~~pursuant ~~loan facility in an amount of up~~ to ~~$365.0~~which ~~million~~it ~~with~~will ~~Credit~~supply ~~Suisse~~Triad AGIsotopes, ~~Cayman Islands Branch, as administrative agent and collateral agent~~Inc. ~~The~~(“Triad”) ~~net~~with ~~proceeds of the new term facility~~Xenon, ~~together~~Neurolite ~~with cash on hand~~ and ~~the~~Cardiolite ~~net~~products ~~proceeds of a proposed initial public offering of common stock of the Company’s parent company~~and, ~~would~~beginning ~~be used to redeem~~ in ~~full~~2016, ~~the~~TechneLite ~~Company’s outstanding $400~~generators.0 ~~million~~The ~~aggregate~~agreement ~~principal~~specifies ~~amount~~pricing oflevels ~~9.750% Senior Notes due 2017, to repay amounts~~and ~~outstanding~~requires ~~under~~Triad ~~its revolving credit facility and~~ to ~~pay~~purchase ~~related~~minimum ~~premiums,~~volumes ~~interest and expenses. The consummation~~ of ~~the~~certain ~~new~~products ~~term~~from ~~loan facility will be conditioned upon~~ the ~~closing of the initial public offering. There can be no assurance that the~~ Company ~~will enter into the new credit facility or that the initial public offering will occur~~.

The ~~information~~agreement inexpires ~~this~~on ~~Form 8-K shall not be deemed “filed” for purposes of Section~~December ~~18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section~~31, ~~nor~~2017 ~~shall~~and itmay be ~~deemed incorporated by reference in any filing~~terminated ~~under~~upon the ~~Securities~~occurrence ~~Act~~ of ~~1933~~specified ~~or the Exchange Act~~events, ~~except~~including asa ~~expressly~~material ~~set~~breach ~~forth~~ by ~~specific~~the ~~reference~~other inparty ~~such~~and acertain ~~filing~~force majeure events.

~~Item~~The 9information furnished in this Item 8.01 ~~Financial~~shall ~~Statements~~not ~~and~~be ~~Exhibits~~deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filing.

~~(d) Exhibits~~Safe Harbor for Forward-Looking and Cautionary Statements

~~None~~This current report contains forward-looking statements. Forward-looking statements are based on our current expectations and assumptions regarding our business and other future conditions. Such forward-looking statements are subject to risks and uncertainties that may be described from time to time in the Company’s filings with the Securities and Exchange Commission. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. The matters referred to in the forward-looking statements contained in this current report may not in fact occur. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LANTHEUS MEDICAL IMAGING, INC. By: /s/ Michael P. Duffy Name: Michael P. Duffy Title: Vice President and General Counsel


	LANTHEUS MEDICAL IMAGING, INC.

	By:	/s/ Michael P. Duffy
	Name:	Michael P. Duffy
	Title:	Vice President and General Counsel

Date: June 22, 2015

Date: June 9, 2015

Filing Compare · Lantheus Medical Imaging, Inc.